Glaxosmithkline will cut jobs amid tough competition from generic drug manufacturers and after sales of its diabetes medicine, Avandia, slumped by almost 40%. Daily Telegraph, Independent

GSK, which employs over 100,000 people, including 20,000 in the UK, plans to make cuts across its sales force, research and development and manufacturing to make annual pre-tax savings of £700m by 2010.